NCT07165132View on ClinicalTrials.gov

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

104

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

October 31, 2032

Conditions

GEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor DiseaseNeuroendocrine TumorsCarcinoidCarcinoid TumorPancreatic NETSolid TumorSomatostatin Receptor

Interventions

DRUG

RYZ401

Ac-225

All Listed Sponsors

lead

RayzeBio, Inc.

INDUSTRY